Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In conclusion, this systematic review and meta-analysis of 100 952 patients across 15 large clinical trials provides comprehensive evidence that SGLT2 inhibitors improve cardiovascular outcomes in ...